Sciensus - Rare Disease Services

New partnership announcement: Sciensus partners with Sentynl Therapeutics, Inc. to become the exclusive distribution partner of NULIBRY® (fosdenopterin) in Europe. Sciensus will deliver both an early access programme and distribution services to support the market access and reimbursement processes of NULIBRY® in Europe. "In partnership with Sciensus, we are proud to extend the reach of this innovative treatment to meet the needs of patients with MoCD Type A in Europe. This partnership marks another step forward in our mission to expand patient access to life-changing rare disease treatment.” said Matt Heck, President & Chief Executive Officer of Sentynl. To read the full press release, visit: https://lnkd.in/er5F4SEY #Sentynl #Partnership #RareDiseases #OrphanDrugs #EAP #expandedaccessprogrammes #insights

At Sciensus, we recognise that not every patient is the same: some simply require more support than others to stay on their regimens. For this reason, we deploy digitally enabled patient support programs to enhance patient outcomes beyond the simple utilisation of the medicines. Hear from Mathieu Loiseau, Director of Rare Clinical Services. Learn more: https://lnkd.in/e5PtQYet #RareDisease #OrphanDrugs #ClinicalSupport #PatientOutcomes

Next month, on February 28, #RareDiseaseDay2025, Sciensus plans to honor the three hundred million people worldwide living with a rare disease. Their resilience, strength, and determination inspire us all. Let us raise global awareness, support research, and work together towards better treatments and a brighter future for everyone affected by rare diseases. More details regarding our Webinar to come, but please consider joining us on this special day. #Sciensus, #RareDiseaseDay, #300MillionStrong, #SupportRare, #RareWarriors, #FightForRare, #RareDiseaseAwareness, #HopeForRare, #TogetherForRare, #RareDiseaseResearch, #StrongerTogether

The number of people living with a rare disease equals the population of the world’s 3rd largest country, with 300 million people impacted globally. As we approach Rare Disease Day, we want to shine a light on the challenges faced by these individuals and the importance of continued research and support. Join us in raising awareness and advocating for those affected by rare diseases. Visit rarediseaseday.org to learn more. #RareDiseaseDay #RareDiseases #LightUpForRare #RareDiseaseAwareness #ShareYourColours

In our latest blog, Andrew Cummins explores the strategic timing for launching expanded access programs (EAPs), the complexities of the European regulatory environment, and the potential these programs have for both patients and biotech firms. Discover expert insights on how to align your EAP with your development and commercialisation strategy. Read more here: https://lnkd.in/ehSxvpng #RareDiseases #EarlyAccessPrograms

Launching a rare orphan drug in Europe and beyond comes with unique challenges and heightened pressure. We have a global network of experts dedicated to getting rare and orphan drugs to hard-to-reach patients in Europe. With a tailored end-to-end solution, Sciensus can unlock access to Europe and beyond with an efficient, high-impact approach that accelerates revenue. To learn more, visit: https://lnkd.in/e5PtQYet #RareDiseases #OrphanDrugs #PatientAccess

Did you know that more than 300 million people worldwide are living with a rare disease? While rare diseases are individually uncommon, together they represent a critical global health challenge. Visit rarediseaseday.org to learn more and join us in raising awareness. #RareDiseaseDay #RareDiseases #LightUpForRare #RareDiseaseAwareness #ShareYourColours

We’re a European network dedicated to getting medicines for rare and orphan diseases to hard-to-reach patients across Europe. For over 30 years, we’ve delivered on every aspect of this vital transaction; from early access all the way to full commercialisation, including patient support programs. To learn more, visit: https://lnkd.in/e5PtQYet #RareDiseases #OrphanDrugs #EAP #PSP Anthony Brackner Andrew Cummins Mathieu Loiseau

Excited to Connect at BIO Partnering @JPM Week! Sciensus is making waves at the JP Morgan Healthcare conference in San Francisco! Alastair Macdonald, Vice President of Medical Affairs, and I are here at the Marriott Marquis, exploring groundbreaking opportunities in rare disease product commercialization across Europe. We've already had incredible conversations this morning and have slots available tomorrow and Wednesday for US partners seeking European market entry. Want to discuss how we can help bring innovative rare disease treatments to the EU market? Let's connect! Available slots: Tuesday & Wednesday Location: JPM Week, San Francisco Marriott Marquis #JPMPresentations #RareDiseases #LifeSciences #HealthcareInnovation #PharmaEurope #BiotechNetworking #DrugCommercialization #OrphanDrugs #GlobalHealth #MedicalBreakthroughs #BIOPartnerships #JPMSanFrancisco

For biotech companies based outside of Europe, setting up an expanded access program (EAP) in Europe may seem daunting. However, with the right partners and strategies, you can design and run a successful EAP without a direct European presence. There are several steps that international biotechs can take to ensure the success of their European EAP. Read our latest blog to find out more: https://lnkd.in/eDNEPqJz #EAP #RareDiseases #OrphanDrugs #ExpandedAccessPrograms